🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Metabolomics Analysis According to the Retinal Nerve Fiber Layer in Patients With NOHL Mutations (MétabOCT)

RecruitingNAAges 18 Years - 60 YearsAllHôpital Necker-Enfants Malades
NCT06682819 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Leber hereditary optic neuropathy (LHON), due to mitochondrial DNA (mtDNA) mutations, is responsible for profound visual impairment. However, there is evidence that optic nerve damage begins before vision declines. There is no biomarker to determine when optic nerve damage begins before visual acuity decline occurs. We hope that the analysis of metabolomics will reveal specific metabolomic profiles and different vitamin B3 and B9 levels depending on whether there are OCT signs of optic nerve damage in healthy patients with mtDNA mutations suggestive of LHON (11778, 3460 or 14484). The existence of an increase in the thickness of the optic fiber layer, whose normal values are well established, constitutes such a sign in favor of optic nerve damage.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patient carrying an mtDNA mutation suggestive of NOHL (11778, 3460 or 14484) with normal visual acuity and who has never had optic neuropathy, or Patient not carrying an mtDNA mutation suggestive of NOHL (11778, 3460 or 14484) with normal visual acuity and who has never had optic neuropathy; * Patient agreeing to undergo an OCT; * Patient agreeing to sign the informed consent; * Patient affiliated to French social protection (Primary Health Insurance Fund, CMU, etc.) or European social protection. Exclusion Criteria: * Patient with or having had optic neuropathy regardless of its etiology * Patient with glaucoma regardless of its etiology; * Patient not wanting to undergo OCT; * Patient not wanting to sign the informed consent; * Patient not affiliated with French social protection (Primary Health Insurance Fund, CMU, etc.) or European. * Patients less than 18 years old or over 60 years old * Pregnant patient
💊

What it tests

  • Optical coherent tomography
📍

Where

1 site
HEGP
Paris, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy